Table 1_Efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable es

Chinese real-world data from 113 patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) treated between January 2021 and December 2023 at the National Cancer Centre of China. The dataset integrates results from a network meta-analysis of clinical trials and a retrospective cohort study, analyzing pathological response rates and survival outcomes. It was authored by Mengfei Sun and last updated in March 2026.

Use Cases

• Compare the efficacy of different neoadjuvant immunotherapy regimens based on pathological complete response (pCR) and major pathological response (MPR) rates.
• Assess the association between treatment factors (like radiotherapy) and survival outcomes (OS/PFS) using multivariate analysis results.
• Evaluate the safety profiles of different regimens based on adverse event (AE) incidence data.
• Validate surrogate endpoints for long-term survival in ESCC based on the reported link between MPR and survival.

Strengths

• Integrates two study types: a network meta-analysis of clinical trials and a real-world cohort of 113 patients.
• Reports specific comparative efficacy metrics, such as a 46.9% vs 12.5% MPR rate difference between two treatment groups.
• Identifies independent prognostic factors (MPR, primary tumor T response) for survival through multivariate analysis.

Limitations

• The primary data file is a 28.1 KB DOCX document, suggesting limited raw data scope and likely containing summarized results rather than patient-level records.
• Row count and column-level documentation are unknown, making detailed reproducibility and secondary analysis difficult.
• The real-world data is from a single center in China, which may limit generalizability to other populations.

Provenance

Source

National Cancer Centre of China (for real-world patient cohort); systematic review of databases including PubMed, Embase, Web of Science, and CNKI.

Collection Method

Retrospective collection of clinical data for real-world cohort; systematic search and network meta-analysis for trial data.

Time Range

Real-world patient data from January 2021 to December 2023.

Freshness

Last updated 2026-03-18 07:36:05

Geography

Focus on China, where over half of global ESCC cases occur.